Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitors, according to a two-year, follow-up analysis of the ICARIA-MM study However the CD38-directed monoclonal antibody may find it difficult to make its mark in the Australian setting any time soon. The study, published...Continue Reading
Watch this excellent presentation by Dr Rob Weinkove of the Malaghan Institute, courtesy of Leukaemia & Blood Cancer NZ, on ‘COVID-19 and haematology patients – protecting yourself in 2022’.Continue Reading
A global panel of experts convened by the International Myeloma Society has published consensus guidelines and recommendations for the prevention of infection in multiple myeloma, which remains the leading cause of morbidity and mortality in patients despite advances in treatment response.Continue Reading
The Medicine Gap was created by a group of concerned New Zealanders who believe the Government must address this country’s escalating medicines crisis. It aims to provide a collective voice to the thousands of sick and vulnerable New Zealanders who can’t afford life-transforming or life-saving drugs to live. This week they covered Multiple Myeloma with two voices....Continue Reading
On Demand Webinar by thelimbic live From the comfort of your own desk (or armchair) … watch the latest event in Myeloma Australia’s MAGIC myeloma case series in your own time. Dr Nicholas Weber leads an expert panel and live audience as they problem solve VRD refractoriness, mobilisation failure and lenalidomide maintenance in 3 challenging...Continue Reading
By Selina Wellbelove – 15 Nov 2021 Vaccinated patients with blood cancers experiencing breakthrough COVID-19 infections remain at high risk for severe or critical disease and death, new research shows. Furthermore, it was found that patients with lymphomas were more at risk than those with other haematological malignancies. The study, led by Dr Livio Pagano,...Continue Reading
A study showing fatigue is common and enduring in non-Hodgkin lymphoma (NHL) survivors has highlighted the need for more proactive screening and management in blood cancer patients, an Australian occupational therapist says. The US study, which assessed fatigue’s prevalence and persistence in 555 NHL survivors, found it occurred in more than a quarter of patients at...Continue Reading
Nichola Oakenfull is partially vaccinated against Covid-19, but she’s still scared. The Wellington woman was diagnosed with multiple myeloma (a type of blood cancer) during alert level 3 last year – a diagnosis that may reduce the efficacy of the Pfizer vaccine. “It is very scary because I’m doing as much as I can to try and keep myself safe, but you are relying...Continue Reading
